Antibody Information
General Information of This Antibody
| Antibody ID | ANI0UWTSU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Atezolizumab |
|||||
| Brand Name | TECENTRIQ |
|||||
| Organization | Genentech, Inc.; Roche Holding AG |
|||||
| Indication | Non-small cell lung cancer; Breast cancer; Renal cancer; Melanoma; Bladder cancer; Renal cell carcinoma; Triple-negative breast cancer; Urothelial carcinoma |
|||||
| Approval Date | May. 2016 |
|||||
| Synonyms |
MPDL3280A; RG7446; 0INE2SFD9E; MPDL-3280A; RG7446; RG-7446; TECENTRIQ
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Programmed cell death 1 ligand 1 (CD274) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| PDB ID | ||||||
| DrugBank ID | ||||||
| Drug Central ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GFTFSDSW
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
ISPYGGST
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
ARRHWPGGFDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QDVSTA
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
SAS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQYLYHPAT
Click to Show/Hide
|
|||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Half Maximal Effective Concentration (EC50)
|
0.9
|
nM
|
||||
|---|---|---|---|---|---|---|
| Antibody Function | Confirm the effect of the drug conjugation with the anti PD-L1 mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | Enzyme-linked immunosorbent assay (ELISA) was performed on ADC 3 to assess their affinities for the PD-L1 protein. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PDL1-Dox ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.25 uM
|
Positive PDL1 expression (PDL1+++/++) | ||
| Method Description |
The MTT-based cytotoxicity assay in MDA-MB-231 cells that displayed a dose dependent cell killing of PDL1-Dox treatment.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
PD-L1 ADC 3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
9.75 nM
|
High PD-L1 expression (PD-L1+++) | ||
| Method Description |
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
|
||||
| In Vitro Model | Lung adenocarcinoma | PC-9 cells | CVCL_B260 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
10.33 nM
|
High PD-L1 expression (PD-L1+++) | ||
| Method Description |
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
11.94 nM
|
High PD-L1 expression (PD-L1+++) | ||
| Method Description |
The in vitro cytotoxicity of ADC 3 was quickly evaluated in three PD-L1-positive cell lines, ie, MDA-MB-231, PC 9, and A431, and one PD-L1-negative cell line, ie, Romas.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
39914224 Ate-37 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.27 nM
|
Positive PD-L1 expression (PD-L1+++/++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 cells | CVCL_0022 | ||
39914224 Ate-38 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
8.01 nM
|
Positive PD-L1 expression (PD-L1+++/++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 cells | CVCL_0022 | ||
39914224 Ate-39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15.88 nM
|
Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
25.55 nM
|
Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
25.7 nM
|
Positive PD-L1 expression (PD-L1+++/++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 cells | CVCL_0022 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
68.49 nM
|
Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
40460724 ADC A9 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.28 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.36 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.62 uM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the BxPc-3 cell.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.4 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the AsPc1 cell.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPc1 cells | CVCL_0152 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.25 uM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the CFPAC cell.
|
||||
| In Vitro Model | Cystic fibrosis, Pancreatic ductal adenocarcinoma | CFPAC cells | CVCL_1119 | ||
40460724 ADC A10 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.39 uM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the BxPc-3 cell.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.39 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.53 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.4 uM
|
Low HER2 expression (HER2+) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the AsPc1 cell.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPc1 cells | CVCL_0152 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
8.05 uM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the CFPAC cell.
|
||||
| In Vitro Model | Cystic fibrosis, Pancreatic ductal adenocarcinoma | CFPAC cells | CVCL_1119 | ||
References